NCT03410875 2026-02-12
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
Clinical Trials
10 trialsNCT03155620 2026-02-10
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01709292 2025-10-27
Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02304809 2025-08-01
AcSé
UNICANCER
Phase 2 Active not recruiting
NCT05388123 2025-05-29
Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia
Scripps Health
Phase 2 Active not recruiting
NCT02314481 2025-05-23
DARWINII
University College, London
Phase 2 Active not recruiting
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT03224767 2025-02-18
Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma
Alliance for Clinical Trials in Oncology
Phase 2 Active not recruiting
NCT05068752 2024-09-19
Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer
HonorHealth Research Institute
Phase 2 Active not recruiting